Meta-Review: Adverse effects of inhaled corticosteroids relevant to older patients

Drugs

Volumn 74, Issue 5, 2014, Pages 539-547

  Mattishent, Katharina ^a   Thavarajah, Menaka ^a   Blanco, Patricia ^a   Gilbert, Daniel ^a   Wilson, Andrew M ^a   Loke, Yoon K ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUTICASONE; MOMETASONE FUROATE; GLUCOCORTICOID;

ADVERSE OUTCOME; ASTHMA; CASE CONTROL STUDY; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MEGADOSE; DRUG USE; FRACTURE; HUMAN; HYPERGLYCEMIA; META ANALYSIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; AGE; AGED; CHEMICALLY INDUCED; FRACTURES, BONE; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; AGE FACTORS; AGED; CATARACT; DOSE-RESPONSE RELATIONSHIP, DRUG; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; HYPERGLYCEMIA; PNEUMONIA;

EID: 84900391594     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0202-z     Document Type: Review

References (21)

1. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care, 2010. London; 2010. p. 1-637.
2. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids - implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8:e75221.
3. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. NEJM. 2007;356:775-89.
4. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169:219-29.
5. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66:699-708.
6. Faverio P, Aliberti S, Bellelli G, Suigo G, Lonni S, Pesci A, et al. The management of community-acquired pneumonia in the elderly. Eur J Intern Med. 2013. doi: 10.1016/j.ejim.2013.12.001.
7. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301:513-21.
8. Raissy HH, Kelly HW, Harkins M, Szefler SJ. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med. 2013;187:798-803.
9. O'Byrne PM, Rennard S, Gerstein H, Radner F, Peterson S, Lindberg B, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med. 2012;106:1487-93.
10. Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:189-95.
11. Weatherall M, Clay J, James K, Perrin K, Shirtcliffe P, Beasley R. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009;14:983-90.
12. Weatherall M, James K, Clay J, Perrin K, Masoli M, Wijesinghe M, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy. 2008;38:1451-8.
13. Eurich DT, Lee C, Marrie TJ, Majumdar SR. Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study. Clin Infect Dis. 2013;57:1138-44.
14. McKeever T, Harrison TW, Hubbard R, Shaw D. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest. 2013;144:1788-94.
15. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029-36.
16. Johnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore). 2008;87:329-34.
17. Kwok CS, Loke YK, Woo K, Myint PK. Risk prediction models for mortality in community-acquired pneumonia: a systematic review. Biomed Res Int. 2013;2013:504136. doi: 10.1155/2013/504136.
18. Mortensen EM, Kapoor WN, Chang CC, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis. 2003;37:1617-24.
19. Kaplan V, Clermont G, Griffin MF, Kasal J, Watson RS, Linde-Zwirble WT, et al. Pneumonia: still the old man's friend? Arch Intern Med. 2003;163:317-23.
20. Davydow DS, Hough CL, Levine DA, Langa KM, Iwashyna TJ. Functional disability, cognitive impairment, and depression after hospitalization for pneumonia. Am J Med. 2013;126(615-24):e5.
21. Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J. 2010;35:1003-21.